肿瘤切除与假体功能重建术后早期再手术的危险因素:PARITY试验的二次分析
基于PARITY试验604例下肢肌肉骨骼肿瘤切除并假体功能重建患者的前瞻性数据,155例(25.7%)在术后1年内接受至少1次再手术。多因素Cox回归显示,肿瘤类型(良性侵袭性骨肿瘤对比原发性骨恶性肿瘤)、手术时间和负压伤口治疗使用是术后1年内再手术的独立预测因素。
要点
- 604例中155例(25.7%)在术后1年内接受至少1次再手术。
- 良性侵袭性骨肿瘤对比原发性骨恶性肿瘤的再手术风险HR为0.15(95%CI 0.04-0.63,p=0.01)。
- 手术时间每增加1小时,再手术风险HR为1.15(95%CI 1.10-1.23,p<0.001);使用负压伤口治疗者HR为1.93(95%CI 1.30-2.90,p=0.002)。
核心结论
- 肿瘤类型(良性侵袭性骨肿瘤对比原发性骨恶性肿瘤)、手术时间和负压伤口治疗使用是与肿瘤切除并假体功能重建患者术后1年内再手术相关的独立变量。
- 这些结果有助于根据诊断告知患者和外科医生再手术风险,并强化手术时间作为影响再手术的因素。
- 这些结果也支持进一步研究该患者群体在手术时使用负压伤口治疗。
研究设计与样本
- 本研究为PARITY试验(肿瘤手术预防性抗生素方案试验)的二次分析,评估肿瘤切除并假体功能重建患者早期再手术的危险因素。
- 评估的基线特征包括年龄、性别、肿瘤类型、肿瘤位置、软组织肿块存在、糖尿病、吸烟状态、化疗使用和中性粒细胞减少。
- 记录的手术因素包括手术时间、局部抗生素、银涂层假体、假体固定方式、关节外切除、骨切除长度、切缘、氨甲环酸、术后抗生素、负压伤口治疗和住院时间。
- 采用单变量分析比较术后1年内是否再手术的患者差异,并采用多变量Cox比例风险回归模型探索术后1年内再手术的预测因素。
- 共604例患者纳入分析,其中155例(25.7%)接受至少1次再手术。
主要发现
- 单变量分析中,肿瘤类型(p<0.001)、软组织肿块存在(p=0.045)、手术时间(p<0.001)、负压伤口治疗使用(p=0.010)和住院时间(p<0.001)均与再手术显著相关。
- 多变量分析中,肿瘤类型(良性侵袭性骨肿瘤对比原发性骨恶性肿瘤;HR 0.15,95%CI 0.04-0.63,p=0.01)、手术时间(每增加1小时,HR 1.15,95%CI 1.10-1.23,p<0.001)和负压伤口治疗使用(HR 1.93,95%CI 1.30-2.90,p=0.002)仍是术后1年内再手术的显著预测因素。
关键数值与推荐
- 良性侵袭性骨肿瘤对比原发性骨恶性肿瘤的再手术风险HR为0.15(95%CI 0.04-0.63,p=0.01)。
- 手术时间每增加1小时的再手术风险HR为1.15(95%CI 1.10-1.23,p<0.001)。
- 使用负压伤口治疗的再手术风险HR为1.93(95%CI 1.30-2.90,p=0.002)。
- 证据等级:治疗性II级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncologic resection and endoprosthetic reconstruction of lower-extremity musculoskeletal tumors are complex procedures fraught with multiple modes of failure. A robust assessment of factors contributing to early reoperation in this population has not been performed in a large prospective cohort. The aim of the present study was to assess risk factors for early reoperation in patients who underwent tumor excision and endoprosthetic reconstruction, with use of data from the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial. METHODS: Baseline characteristics were assessed, including age, sex, tumor type, tumor location, presence of a soft-tissue mass, diabetes, smoking status, chemotherapy use, and neutropenia. Operative factors were recorded, including operative time, topical antibiotics, silver-coated prosthetics, endoprosthetic fixation, extra-articular resection, length of bone resected, margins, tranexamic acid, postoperative antibiotics, negative-pressure wound therapy, and length of stay. Univariate analysis was utilized to explore the differences between patients who did and did not undergo reoperation within 1 year postoperatively, and a multivariate Cox proportional hazards regression model was utilized to explore the predictors of reoperation within 1 year. RESULTS: A total of 155 (25.7%) of 604 patients underwent ≥1 reoperation. In univariate analysis, tumor type (p < 0.001), presence of a soft-tissue mass (p = 0.045), operative time (p < 0.001), use of negative-pressure wound therapy (p = 0.010), and hospital length of stay (p < 0.001) were all significantly associated with reoperation. On multivariate assessment, tumor type (benign aggressive bone tumor versus primary bone malignancy; hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.63; p = 0.01), operative time (HR per hour, 1.15; 95% CI, 1.10 to 1.23; p < 0.001), and use of negative-pressure wound therapy (HR, 1.93; 95% CI, 1.30 to 2.90; p = 0.002) remained significant predictors of reoperation within 1 year. CONCLUSIONS: Independent variables associated with reoperation within 1 year in patients who underwent tumor resection and endoprosthetic reconstruction included tumor type (benign aggressive bone tumor versus primary bone malignancy), operative time, and use of negative-pressure wound therapy. These results will help to inform patients and surgeons regarding the risk of reoperation by diagnosis and reinforce operative time as a factor influencing reoperation. These results also support further investigation into the use of negative-pressure wound therapy at the time of surgery in this patient population. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
引用
- Kendal JK, Slawaska-Eng D, Gazendam A, et al. Risk Factors for All-Cause Early Reoperation Following Tumor Resection and Endoprosthetic Reconstruction: A Secondary Analysis from the PARITY Trial. J Bone Joint Surg Am. 2023. PMID: 37466573. doi:10.2106/JBJS.22.00815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。